What are the recommended dosing regimens for baclofen, metoclopramide, gabapentin, haloperidol, chlorpromazine, and midazolam in the treatment of hiccups?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 19, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Recommended Dosing Regimens for Hiccups

For intractable hiccups, chlorpromazine remains the FDA-approved first-line agent at 25-50 mg orally three to four times daily, with baclofen (10 mg three times daily) as the most evidence-supported alternative based on randomized controlled trial data.

Specific Dosing by Medication

Chlorpromazine (FDA-Approved for Hiccups)

  • Oral dosing: 25-50 mg three to four times daily 1
  • If symptoms persist for 2-3 days, parenteral therapy is indicated 1
  • For palliative care/end-of-life settings: 25-100 mg orally or rectally at bedtime 2
  • Intramuscular: 12.5 mg every 4-12 hours, or 3-5 mg/hour IV 3
  • Rectal: 25-100 mg every 4-12 hours 3
  • Usual effective parenteral dose: 37.5-150 mg/day; rectal 75-300 mg/day 3

Clinical note: Chlorpromazine has the strongest regulatory approval but carries significant risks of orthostatic hypotension, extrapyramidal symptoms, and anticholinergic effects 3. Recent systematic reviews confirm complete resolution in multiple case series with 10-25 mg oral/IM doses 4.

Baclofen (Strongest Research Evidence)

  • Standard dosing: 10 mg orally three times daily for 5 days 5
  • Alternative regimen: 45 mg/day (divided doses) 6
  • Evidence quality: This is the only medication studied in a randomized, double-blind, placebo-controlled trial for hiccups, showing significant superiority over placebo (RR 7.00,95% CI 1.91-25.62, p=0.003) 5
  • Mechanism: GABA-B receptor agonist suppressing the "hiccup center" 6

Important caveat: Baclofen can cause CNS side effects (drowsiness, dizziness) and may fail in some patients despite adequate dosing 7.

Gabapentin (Well-Tolerated Alternative)

  • Low-dose regimen: 100 mg twice daily 7
  • Standard regimen: 300 mg three times daily 8
  • Higher dose: 1,200 mg/day (when substituted for failed baclofen) 6
  • Onset: Can work within 24 hours 7
  • Advantages: Minimal drug interactions, particularly valuable in transplant recipients; lacks serious side effects at low doses 7

Haloperidol

  • Dosing: 1-2 mg orally or intramuscularly 4
  • Systematic review evidence shows complete resolution in case series 4
  • Consider when antipsychotic effect needed (e.g., concurrent delirium)

Metoclopramide

  • Evidence: Studied in randomized controlled trials 9
  • Specific dosing not detailed in provided evidence, but has prospective study support 9
  • Mechanism: Prokinetic and dopamine antagonist

Midazolam (Palliative Care/Refractory Cases)

  • Starting dose: 0.5-1 mg/hour continuous infusion, with 1-5 mg as needed for breakthrough 3
  • Usual effective dose: 1-20 mg/hour 3
  • Bolus dosing (adults <55 years): 0.5-4 mg IV slowly 10
  • Continuous infusion: 0.02-0.10 mg/kg/hour (1-7 mg/hour) 10
  • Reserved for end-of-life palliative sedation when other measures fail 3

Treatment Algorithm

First-line approach:

  1. Start with baclofen 10 mg TID if patient can tolerate 5-day trial (strongest RCT evidence) 5
  2. Alternative first-line: chlorpromazine 25-50 mg TID-QID (FDA-approved, but monitor for hypotension and EPS) 1, 4

Second-line (if first-line fails or not tolerated): 3. Switch to gabapentin 100-300 mg BID-TID (excellent safety profile, rapid onset) 7, 8 4. Consider haloperidol 1-2 mg if antipsychotic properties beneficial 4

Refractory cases: 5. Increase gabapentin to 1,200 mg/day 6 6. Trial combination therapy (cisapride + omeprazole + baclofen showed 62% response rate) 6 7. Consider midazolam only in palliative care settings for symptom control at end-of-life 3

Critical Monitoring Points

  • Chlorpromazine: Check orthostatic vital signs; elderly patients particularly vulnerable to hypotension 3, 1
  • Baclofen: Monitor for CNS depression; titrate down gradually to avoid withdrawal 5
  • Midazolam: Requires continuous monitoring for respiratory depression; paradoxical agitation possible 3, 10
  • All antipsychotics: Watch for extrapyramidal symptoms and anticholinergic effects 3

The evidence base consists primarily of case reports and case series, with only baclofen and metoclopramide having RCT data 9, 5. No specific recommendations exist for optimal duration of therapy, but most successful cases show response within days to weeks.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.